Process Implications for Metal‐Dependent Immunoaffinity Interactions

William H Velander, C. L. Orthner, J. P. Tharakan, R. D. Madurawe, A. H. Ralston, D. K. Strickland, W. N. Drohan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Immunosorbents have been developed which utilize metal‐dependent interactions between monoclonal antibody(s) (Mab) and human plasma Protein C and Factor IX, members of the vitamin K‐dependent plasma protein family. In this report, we describe the potential process advantages associated with two different types of divalent metal‐dependent systems: 1) a Mab‐Protein C (antigen) complex which is stabilized in a divalent metal‐free environment and 2) a Mab‐Factor IX (antigen) complex which is stabilized in the presence of divalent metal ions. Chelating agents such as citrate or EDTA are effective agents for sequestering divalent metals. Thus, Protein C binds to the immunosorbent in the presence of EDTA or sodium citrate and can be eluted with buffer containing 25 mM calcium chloride or magnesium chloride. In the second case, Factor IX binds to the immunosorbent in the presence of magnesium chloride and can be eluted with sodium citrate or EDTA. These gentle elution conditions are desirable in order to retain the native structure as well as functional activity of the protein to be immunopurified. Furthermore, unwanted plasma proteins, which may interact nonspecifically with either the agarose matrix or immunoglobulin G (IgG) ligand are less likely to be eluted under these conditions. The calcium‐free citrate buffers used for immunosorption by either of these processes preclude the formation of fibrin solids and eliminate eluents which are difficult to process and which interfere with the biological activity of the product (i.e. chaotropes). The immunoaffinity process we describe for Protein C and Factor IX provides high functionality, purity and yield and demonstrates the feasibility of large‐scale processes utilizing metal‐dependent immunosorbents.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalBiotechnology Progress
Volume5
Issue number3
DOIs
StatePublished - Jan 1 1989

Fingerprint

Immunosorbents
Factor IX
Protein C
Edetic Acid
Blood Proteins
Magnesium Chloride
Citric Acid
Sequestering Agents
Buffers
Metals
Antigens
Calcium Chloride
Chelating Agents
Fibrin
Vitamins
Sepharose
Immunoglobulin G
Monoclonal Antibodies
Ions
Ligands

ASJC Scopus subject areas

  • Biotechnology

Cite this

Velander, W. H., Orthner, C. L., Tharakan, J. P., Madurawe, R. D., Ralston, A. H., Strickland, D. K., & Drohan, W. N. (1989). Process Implications for Metal‐Dependent Immunoaffinity Interactions. Biotechnology Progress, 5(3), 119-125. https://doi.org/10.1002/btpr.5420050310

Process Implications for Metal‐Dependent Immunoaffinity Interactions. / Velander, William H; Orthner, C. L.; Tharakan, J. P.; Madurawe, R. D.; Ralston, A. H.; Strickland, D. K.; Drohan, W. N.

In: Biotechnology Progress, Vol. 5, No. 3, 01.01.1989, p. 119-125.

Research output: Contribution to journalArticle

Velander, WH, Orthner, CL, Tharakan, JP, Madurawe, RD, Ralston, AH, Strickland, DK & Drohan, WN 1989, 'Process Implications for Metal‐Dependent Immunoaffinity Interactions', Biotechnology Progress, vol. 5, no. 3, pp. 119-125. https://doi.org/10.1002/btpr.5420050310
Velander WH, Orthner CL, Tharakan JP, Madurawe RD, Ralston AH, Strickland DK et al. Process Implications for Metal‐Dependent Immunoaffinity Interactions. Biotechnology Progress. 1989 Jan 1;5(3):119-125. https://doi.org/10.1002/btpr.5420050310
Velander, William H ; Orthner, C. L. ; Tharakan, J. P. ; Madurawe, R. D. ; Ralston, A. H. ; Strickland, D. K. ; Drohan, W. N. / Process Implications for Metal‐Dependent Immunoaffinity Interactions. In: Biotechnology Progress. 1989 ; Vol. 5, No. 3. pp. 119-125.
@article{fa825cb1ac6248b1aea68f18c8046e27,
title = "Process Implications for Metal‐Dependent Immunoaffinity Interactions",
abstract = "Immunosorbents have been developed which utilize metal‐dependent interactions between monoclonal antibody(s) (Mab) and human plasma Protein C and Factor IX, members of the vitamin K‐dependent plasma protein family. In this report, we describe the potential process advantages associated with two different types of divalent metal‐dependent systems: 1) a Mab‐Protein C (antigen) complex which is stabilized in a divalent metal‐free environment and 2) a Mab‐Factor IX (antigen) complex which is stabilized in the presence of divalent metal ions. Chelating agents such as citrate or EDTA are effective agents for sequestering divalent metals. Thus, Protein C binds to the immunosorbent in the presence of EDTA or sodium citrate and can be eluted with buffer containing 25 mM calcium chloride or magnesium chloride. In the second case, Factor IX binds to the immunosorbent in the presence of magnesium chloride and can be eluted with sodium citrate or EDTA. These gentle elution conditions are desirable in order to retain the native structure as well as functional activity of the protein to be immunopurified. Furthermore, unwanted plasma proteins, which may interact nonspecifically with either the agarose matrix or immunoglobulin G (IgG) ligand are less likely to be eluted under these conditions. The calcium‐free citrate buffers used for immunosorption by either of these processes preclude the formation of fibrin solids and eliminate eluents which are difficult to process and which interfere with the biological activity of the product (i.e. chaotropes). The immunoaffinity process we describe for Protein C and Factor IX provides high functionality, purity and yield and demonstrates the feasibility of large‐scale processes utilizing metal‐dependent immunosorbents.",
author = "Velander, {William H} and Orthner, {C. L.} and Tharakan, {J. P.} and Madurawe, {R. D.} and Ralston, {A. H.} and Strickland, {D. K.} and Drohan, {W. N.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1002/btpr.5420050310",
language = "English (US)",
volume = "5",
pages = "119--125",
journal = "Biotechnology Progress",
issn = "8756-7938",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Process Implications for Metal‐Dependent Immunoaffinity Interactions

AU - Velander, William H

AU - Orthner, C. L.

AU - Tharakan, J. P.

AU - Madurawe, R. D.

AU - Ralston, A. H.

AU - Strickland, D. K.

AU - Drohan, W. N.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Immunosorbents have been developed which utilize metal‐dependent interactions between monoclonal antibody(s) (Mab) and human plasma Protein C and Factor IX, members of the vitamin K‐dependent plasma protein family. In this report, we describe the potential process advantages associated with two different types of divalent metal‐dependent systems: 1) a Mab‐Protein C (antigen) complex which is stabilized in a divalent metal‐free environment and 2) a Mab‐Factor IX (antigen) complex which is stabilized in the presence of divalent metal ions. Chelating agents such as citrate or EDTA are effective agents for sequestering divalent metals. Thus, Protein C binds to the immunosorbent in the presence of EDTA or sodium citrate and can be eluted with buffer containing 25 mM calcium chloride or magnesium chloride. In the second case, Factor IX binds to the immunosorbent in the presence of magnesium chloride and can be eluted with sodium citrate or EDTA. These gentle elution conditions are desirable in order to retain the native structure as well as functional activity of the protein to be immunopurified. Furthermore, unwanted plasma proteins, which may interact nonspecifically with either the agarose matrix or immunoglobulin G (IgG) ligand are less likely to be eluted under these conditions. The calcium‐free citrate buffers used for immunosorption by either of these processes preclude the formation of fibrin solids and eliminate eluents which are difficult to process and which interfere with the biological activity of the product (i.e. chaotropes). The immunoaffinity process we describe for Protein C and Factor IX provides high functionality, purity and yield and demonstrates the feasibility of large‐scale processes utilizing metal‐dependent immunosorbents.

AB - Immunosorbents have been developed which utilize metal‐dependent interactions between monoclonal antibody(s) (Mab) and human plasma Protein C and Factor IX, members of the vitamin K‐dependent plasma protein family. In this report, we describe the potential process advantages associated with two different types of divalent metal‐dependent systems: 1) a Mab‐Protein C (antigen) complex which is stabilized in a divalent metal‐free environment and 2) a Mab‐Factor IX (antigen) complex which is stabilized in the presence of divalent metal ions. Chelating agents such as citrate or EDTA are effective agents for sequestering divalent metals. Thus, Protein C binds to the immunosorbent in the presence of EDTA or sodium citrate and can be eluted with buffer containing 25 mM calcium chloride or magnesium chloride. In the second case, Factor IX binds to the immunosorbent in the presence of magnesium chloride and can be eluted with sodium citrate or EDTA. These gentle elution conditions are desirable in order to retain the native structure as well as functional activity of the protein to be immunopurified. Furthermore, unwanted plasma proteins, which may interact nonspecifically with either the agarose matrix or immunoglobulin G (IgG) ligand are less likely to be eluted under these conditions. The calcium‐free citrate buffers used for immunosorption by either of these processes preclude the formation of fibrin solids and eliminate eluents which are difficult to process and which interfere with the biological activity of the product (i.e. chaotropes). The immunoaffinity process we describe for Protein C and Factor IX provides high functionality, purity and yield and demonstrates the feasibility of large‐scale processes utilizing metal‐dependent immunosorbents.

UR - http://www.scopus.com/inward/record.url?scp=0024739676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024739676&partnerID=8YFLogxK

U2 - 10.1002/btpr.5420050310

DO - 10.1002/btpr.5420050310

M3 - Article

VL - 5

SP - 119

EP - 125

JO - Biotechnology Progress

JF - Biotechnology Progress

SN - 8756-7938

IS - 3

ER -